Harvard Pilgrim Health Care and University of California, Irvine

First Funded: 1997

Overview: This Epicenter is jointly led by Dr. Richard Platt at the Department of Population Medicine, Harvard Medical School/Harvard Pilgrim Health Care Institute, and Dr. Susan Huang at the Division of Infectious Diseases, University of California, Irvine. It includes the lead organizations’ affiliated hospitals, Partners Healthcare, the University of Massachusetts Amherst, and Hospital Corporation of America.

Research Study Areas:
  • Conduct the Swapout Trial – a cluster-randomized trial to assess the ability of nasal application of iodophor containing ointment to that of mupirocin ointment in ICU patients to prevent serious infection and emergence of antimicrobial resistance.
  • Conduct the CLUSTER Trial – Cluster Linkage Using Statistics to Trigger and Evaluate Response – a cluster randomized trial to compare the utility of statistical tools to current practice for limiting the size and duration of outbreaks of hospital acquired infections.
  • Create new ways to predict which patients with community-acquired pneumonia and urinary tract infections are infected with antibiotic-resistant organisms, and develop effective methods for communicating this information to clinicians.
  • Compare clinical outcomes in non-critically ill patients admitted to the hospital with pneumonia and started empirically on standard-spectrum, versus extended-spectrum, antibiotic therapy.
  • Determine the impact of the Medicare pay-for-reporting sepsis management bundle on processes of care, clinical outcomes, and administrative coding.
  • Develop an objective, electronically-computable surveillance definition for hospital-acquired pneumonia not related to ventilator use.

Principal Investigator: Richard Platt, MD, MS (Joint-PI)External and Susan Huang, MD, MPH (Joint-PI)External